Shares of Scholar Rock (SRRK) rose about 2% on Tuesday morning after falling 12% in the pre-market session after the U.S.

The FDA has issued a Complete Response Letter to Scholar Rock regarding the BLA for apitegromab for the treatment of spinal muscular atrophy.

Using a specially designed back brace in addition to physical therapy worked better to ease scoliosis in children with SMA ...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and ...

The complete response letter was issued by the FDA during a routine inspection of a third-party fill-finish facility, not ...

The FDA has rejected apitegromab as a treatment for spinal muscular atrophy due to issues at a manufacturing facility.

See why Scholar Rock Holding Corporation remains a Strong Buy despite regulatory setbacks, with key catalysts ahead and ...

Investing.com -- Scholar Rock (NASDAQ:SRRK) stock fell 14% Tuesday after the U.S. Food and Drug Administration (FDA) issued a ...

Scholar Rock (NASDAQ:SRRK) shares fell 14% on Tuesday following the U.S. Food and Drug Administration’s (FDA) issuance of a Complete Response Letter (CRL) regarding the company’s spinal muscular ...